IBRX 8-K: SEC filing
Filed with the SEC on · accession 0001326110-26-000097
IBRX filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
ImmunityBio, Inc. furnished a press release announcing its financial results for the three and nine months ended September 30, 2026, and provided a business update.
Key details
✦ Ask GOAX AI about this filing — what it means for IBRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for IBRX?
Click hereFrequently asked questions
What did IBRX file with the SEC on Nov 9, 2026?
IBRX filed a 8-K (SEC filing). ImmunityBio, Inc. furnished a press release announcing its financial results for the three and nine months ended September 30, 2026, and provided a business update.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other IBRX SEC filings
Get alerts when IBRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days